Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment ...

Louvain-la-Neuve, Belgique, le 20 août 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de proto ...

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 31,971,783 A shares and 109,162,495 B shares. The number of votes of the company's shares is ...

IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer and Heidelberg ...

Webcasts for these conferences may be accessed at the “Events” section of the Company’s website. A replay of these webcasts will be available on the Arcutis website for 180 days following the ...

About Rezdiffra Rezdiffra is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. It is the first approved medication for the treatment of MASH in the US ...

The SmartVascular Dx test is essential for the early detection of vascular disease, which is a significant health concern in many communities. Its capabilities enable timely and targeted interventions ...

The financing consists of a combination of a $36 million line of credit and a $14 million contingent private placement. The line of credit is available immediately and allows Tevogen Bio to access up ...

JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza ...

NMDP Unite brings together blood stem cell donors, transplant recipients, caregivers, and supporters, all united by one mission: to find cures and give hope to patients facing life-threatening blood ...

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635 (c) (4).

"This move by the Board of Directors aligns with our current goal of reducing the share count." said Giorgio R. Saumat, CEO of ETST. "It sends a clear signal to the investment community: we are ...